Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Candel Therapeutics (Nasdaq: CADL) reported that on August 31, 2026, its Board Compensation Committee granted inducement stock options to two new employees for an aggregate of 31,400 shares of common stock at an exercise price of $13.07 per share under the 2025 Inducement Plan.
According to Candel Therapeutics, the options vest 25% on the first anniversary of each employee’s start date, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service. The awards were approved as employment inducements in line with Nasdaq Listing Rule 5635(c)(4). The 2025 Inducement Plan was adopted by the Board on December 24, 2025.
News Explained
The August 31 grants are options to purchase up to 31,400 common shares at
Details
News Market Reaction – CADL
On Sep 2, the first trading day after this news, CADL closed 2.72% above the previous close. Our momentum scanner recorded 2 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- Grant date
- August 31, 2026
- Inducement awards
- Employees receiving grants
- 2 employees
- New employees
- Shares under options
- 31,400 shares
- Aggregate inducement stock options
- Exercise price
- $13.07 per share
- Inducement stock options
- Initial vesting
- 25%
- On the first anniversary of the employee's start date
- Remaining vesting
- 75%
- After the first anniversary
- Monthly vesting period
- 36 equal monthly installments
- Remaining inducement options
- Inducement Plan adoption date
- December 24, 2025
- 2025 Inducement Plan adopted by the Board
Historical Context
-
September investor conference participation was announced; shares declined 2.35% over 24 hours.
-
Quarterly results, clinical progress, and cash resources were reported; shares gained 10.63%.
-
Options covering 30,800 shares were granted; shares gained 4.37% over 24 hours.
-
Extended Phase 3 data presentation at ASTRO was announced; shares gained 0.6%.
-
Canaccord Growth Conference participation was announced; shares declined 2.89%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
inducement stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on August 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 31,400 shares of the Company’s common stock, with a per share exercise price of
The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to
The above-described awards were each granted as inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA) and published in The Lancet Oncology. The FDA also granted Fast Track Designation, Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.
Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.